| Synthetic introns to enable mutation-dependent targeting of cancer cells | Omar Abdel-Wahab, MD |
| Imaging the efficacy of TRAIL-enhanced cancer immunotherapy | Prasad Adusumilli, MD and Vladimir Ponomarev, MD, PhD |
| Small molecule degrader of HMGCS1 to harness the mevalonate pathway in cancer | Heeseon An, PhD |
| Self-immolative tumor-targeted nanogenerators | Christophe Antczak, PhD |
| Imiquimod analogs as new cancer immunotherapy agents | Daniel Bachovchin, PhD |
| New DPP8/9-binding ligands for the treatment of acute myeloid leukemia | Daniel Bachovchin, PhD |
| Induction of pyroptosis for cancer monocytic/macrophage lineage | Daniel Bachovchin, PhD |
| Peptidase Inhibitors as New Cancer Immunotherapy Agents | Daniel Bachovchin, PhD |
| ID protein degradation as a therapeutic strategy for advanced cancers | Robert Benezra, PhD; James Harding, MD |
| Tumor endothelial cell-specific inhibitor for Id-proteins | Robert Benezra, PhD |
| Over expression of asmase in endothelial stem cells by lentiviral vector delivery | Nira Bloom, PhD |
| Expression and modulation of Fcγ receptors on human dendritic cells for targeted immunotherapy | Adam Boruchov, MD |
| Mesoporous silica nanoparticles as drug delivery vehicles in a PDGFB-driven murine high grade glioma model | Michelle Bradbury, MD, PhD |
| Construction and characterization of retroviral vectors encoding genes capable of generating both primary and efficient co-stimulatory signals to T cells for use in the adoptive immunotherapy of B cell malignancies | Renier Brentjens, MD, PhD |
| Development and characterization of novel inhibitors of JAK kinases | Jacqueline Bromberg, MD, PhD |
| Induction of natural EGFR inhibitors | Luca Cartegni, PhD |
| Therapeutic modulation of alternative splicing | Luca Cartegni, PhD |
| Overcoming CDK4/6 inhibitor resistance | Sarat Chandarlapaty, MD, PhD |
| Therapeutic targeting of Gαq pathway in uveal melanoma | Yu Chen, PhD |
| Development of small molecule inhibitors of MCL-1 for cancer therapy | Emily Cheng, PhD |
| Using Self-Assembling DisAssembling (SADA) Platform in Pretargeted Radioimmunotherapy and DNA Damage Repair Inhibitors to Enhance Immunogenic Cell Death | Nai-Kong Cheung, MD, PhD |
| Dual specific human monoclonal antibody targeting IGF-I and IGF-II for treating cancer in children | Nai-Kong Cheung, MD, PhD |
| Multistep targeting of GD2 using DOTA hook | Nai-Kong Cheung, MD, PhD |
| Optimizing radioimmunotherapy delivered through cerebrospinal fluid: Testing affinity-matured scFv constructs in xenograft models | Nai-Kong Cheung, MD, PhD |
| Humanized antibody targeting CSPG4 on melanoma | Nai-Kong Cheung, MD, PhD |
| SADA DOTA-PRID and SADA DOTA-PRIT for incurable cancers | Nai-Kong Cheung, MD, PhD; Darren Veach, PhD |
| T cell-engaging bispecific antibody (TCE bsAb) therapeutics in DLK1-positive cancer | Ping Chi, MD, PhD |
| Therapeutic and diagnostic targeting of DLK1 in cancer | Ping Chi, MD, PhD |
| Development of the epichaperome inhibitor LSI-137 | Gabriela Chiosis, PhD |
| Novel compounds inhibiting Hsp90 | Gabriela Chiosis, PhD and Neal Rosen, MD, PhD |
| Development of novel Hsp70 ATPase activity modulators | Gabriela Chiosis, PhD |
| PU24FCl, a novel selective Hsp90 inhibitor | Gabriela Chiosis, PhD |
| Bcr-Abl substrates and inhibitors | Bayard Clarkson, MD |
| Leptin receptor as a target to eradicate CML tumor initiating cells | Bayard Clarkson, MD |
| Design of molecular glue degraders to selectively target ERK2 over ERK1 | Arvin Dar, PhD |
| Development of D-peptide inhibitors of oncogenic KRAS mutants | Samuel Danishefsky, PhD |
| Testing the immunogenicity of a new unimolecular hexavalent vaccine in combination with the novel synthetic saponin adjuvant SQS-1-0-5-5 | Samuel Danishefsky, PhD |
| Cell migration inhibition: synthesis and evaluation of migrastatin and analogues for the identification of a novel chemotherapeutic | Samuel Danishefsky, PhD |
| Preparation of multiple drug reversal agent 5-N-acetyl-ardeemin and some active analogues | Samuel Danishefsky, PhD |
| Synthesis and evaluation of a novel unimolecular multiantigenic vaccine against breast cancer | Samuel Danishefsky, PhD |
| Telomerase inhibition: Synthesis and evaluation of UCS1025A and analogues for the identification of a novel chemotherapeutic | Samuel Danishefsky, PhD and Malcolm Moore, D.Phil. |
| Development of an AML-directed dual-targeted CAR T cell | Anthony Daniyan, MD |
| Targeting DJ-1 for cancer therapy | Yael David, PhD |
| Synthesis of a multi-scaffold library for high-throughput screening for novel inhibitors of androgen receptor signaling | Christine DiBlasi, PhD |
| Synthetic study on proteasome inhibitor salinosporamide A | Atsushi Endo, PhD |
| Novel enhancement strategies for cancer DNA vaccines: Epitope optimization and fusion vectors | Manuel Engelhorn, PhD |
| Development of reagents to antagonize ceramide-mediated raft clustering in vivo | Zvi Fuks, MD |
| High throughput screening of specific inhibitors for kinase suppressor of Ras1 (KSR1) | Zvi Fuks, MD |
| ASMase gene therapy for radiosensitization | Zvi Fuks, MD and Richard Kolesnick, MD |
| Preclinical development of anti-ceramide monoclonal antibodies | Zvi Fuks, MD |
| Preclinical evaluation of KSR phosphorothioate antisense oligonucleotides in treating gf Ras-dependent human malignancies | Zvi Fuks, MD and Richard Kolesnick, MD |
| The development of highly concise routes to epothilones in the context of the chemical synthesis of the promising antitumor agent 4-desmethyl-12,13-desoxyEpothilone B | Ana Gabarda Ortega, PhD |
| L1CAM targeting 1xx CAR T cells for advanced solid tumors | Karuna Ganesh, MD, PhD |
| Targeting hematopoietic stem cells with lipid nanoparticles to potentiate cancer immunotherapy | Alexander Gitlin, MD, PhD |
| Design of small molecules that trigger secretion of neoantigen: Chaperone complexes | Jonathan Goldberg, PhD |
| Mechanism of TEM8 in increasing CD8 T cell responses | Polly Gregor, PhD |
| ROS-activatable prodrug of Doxazoline | Jan Grimm, MD, PhD |
| Clinically approved nanoparticles as environmental-responsive self reporting drug delivery system | Jan Grimm, MD, PhD |
| Multimodality theranostics of pancreas cancer | Jan Grimm, MD, PhD |
| Gene expression profiling to identify therapeutic targets in chronic lymphocytic leukemia | Mark Heaney, MD, PhD |
| In Situ CAR T cell engineering for treatment of high grade serous ovarian cancer | Daniel Heller, PhD |
| Targeted nanoformulation and delivery strategy to improve the utility of PROTACS | Daniel Heller, PhD |
| Nanoscale bio-imaging | Daniel Heller, PhD |
| ZIC1: Therapeutic target and predictor of outcome in adult male germ cell tumors | Jane Houldsworth, PhD |
| Biodistribution and radiobiological effectiveness of 225Ac and 213Bi for alpha-particle radioimmunotherapy | John Humm, PhD |
| Targeting isocitrate dehydrogenase mutations by enzyme hyperactivation | Andrew Intlekofer, MD, PhD |
| Novel combination therapies for ER+/HER2- breast cancer | Xuejun Jiang, PhD |
| Identification of chemical inhibitors of the ULK1 kinase complex | Xuejun Jiang, PhD and Derek Tan, PhD |
| Development of novel therapies for endometrial carcinomas | Xuejun Jiang, PhD; Neal Rosen, MD, PhD |
| Identification and characterization of small molecule inhibitors of Apaf-1/Cytochrome c-mediated apoptosis | Xuejun Jiang, PhD and Derek Tan, PhD |
| Targeting the PTEN ubiquitin ligase NEDD4 with a novel electrophilic fragment library | Xuejun Jiang, PhD and Derek Tan, PhD |
| Protein corona engineered lipid nanoparticle (PRO-LNP) for targeted macromolecular drug delivery | Alex Kentsis, MD, PhD |
| A modular platform for cell specific macromolecular drug delivery | Alex Kentsis, MD, PhD |
| Chemical library screen for musashi inhibitors | Michael Kharas, PhD |
| Inhibition of MSI translation in MSI driven leukemias | Michael Kharas, PhD |
| Tunable peptidomimetic nanoconjugates for cancer gene control | Alex Kentsis, MD, PhD |
| Metabolic engineering to enhance CAR T cell therapy | Kayvan Keshari, PhD |
| IL10 blockade as a novel immunotherapy across solid cancers | Danny Khalil, MD, PhD |
| Molecular glues targeting stem cell/immuno oncologic programs in cancer | Michael Kharas, PhD |
| Developing MUSASHI RNA binding protein inhibitors to target cancer | Michael Kharas, PhD |
| Raman nanostar-triggered automated laser ablation device | Moritz Kircher, MD, PhD and Ricardo Toledo-Crow, PhD |
| ENT1 requres ceramide-rich platforms to transport nucleoside chemotherapeutics | Richard Kolesnick, MD |
| C16:0 ceramide nano-liposomes reverse multi-drug resistance | Richard Kolesnick, MD |
| Sphingolipid-based anti-angiogenic chemosensitization | Richard Kolesnick, MD |
| Acid sphingomyelinase is obligate for gemcitabine action | Richard Kolesnick, MD |
| Small animal imaging and spectroscopy | Jason Koutcher, MD PhD |
| Leveraging living drugs for tumor-targeted radiotherapy | Simone Krebs, MD |
| Pre-clinical development of a novel class of proteasome inhibitors | Marc Ladanyi, MD |
| Improved detection of abl, c-kit, src and PDGFRα expressing tumors using a combination of positron labeled EGFR tyrosine kinase inhibitors and “stealth” nanocarriers | Steve Larson, MD |
| Ac-225 DOTA Proteus for Pre-targeted Radioimmunotherapy (PRIT) of solid tumors | Steven Larson, MD |
| Alpha and Beta Pre-targeted Radioimmunotherapy for Peritoneal Carcinomatosis | Steven Larson, MD |
| Targeting FGFR3 oncogenic mutation for theranostics | Jason Lewis, PhD |
| Statins to Enhance Pretargeted Radioimmunotherapy of HER2-expressing Esophagogastric Tumors | Jason Lewis, PhD |
| Amplifying the efficacy of pretargeted radioimmunotherapy (PRIT) in pancreatic cancer | Jason Lewis, PhD |
| Radiosensitization of malignant gliomas by gene therapy | Gloria Li, PhD and Philip Gutin, MD |
| Targeted delivery of attenuated interleukin-15 for ILC1-mediated cancer immunotherapy | Ming Li, PhD |
| Targeting TGF-β signaling in CD4+ T cells for cancer immunotherapy | Ming Li, PhD |
| Development of lysosomal inhibitors for pancreatic cancer treatment | Yueming Li, PhD |
| Development of the autophagy-lysosome pathway blockers for pancreatic cancer treatment | Yueming Li, PhD |
| Development of sulfonamide γ-secretase inhibitors for cancer therapy | Yueming Li, PhD |
| Preclinical studies of sulfonamide γ-secretase inhibitors for cancer therapy | Yueming Li, PhD |
| γ-Secretase: Target validation and inhibitor development | Yueming Li, PhD |
| Target notch signal pathway in B-cell neoplasm | Yueming Li, PhD |
| Identification and characterization of small molecule enhancers of GTPase activity | Piro Lito, MD |
| Advancing uPAR CAR T cells towards clinical trials in cancer | Scott Lowe, PhD |
| Harnessing senolytic CAR T cell based therapies for the treatment of solid tumors | Scott Lowe, PhD |
| Targeting p53-regulated metabolism for anti-leukemia therapy | Scott Lowe, PhD |
| Advancing CARM1 Inhibitors as Preclinical Candidates Against Metastatic Breast Cancer | Minkui Luo, PhD |
| Developing mechanism-based protein arginine methyltransferase inhibitors as anti-cancer reagents | Minkui Luo, PhD |
| Develop protein methyltransferase inhibitors as anti-cancer drugs | Minkui Luo, PhD |
| High-throughput screening for SETMAR inhibitors: Develop protein methyltransferase inhibitors as anticancer drugs | Minkui Luo, PhD |
| High throughput screening for SETMAR inhibitors | Minkui Luo, PhD |
| TREX1 exonuclease inhibitor to improve antitumor immunity | John Maciejowski, PhD |
| Synthesis of polyketide-like small molecule libraries | Daniel Macks, PhD |
| Effect of histone deacetylase inhibitors on normal and transformed prostate cells | Paul Marks, PhD |
| Monitoring molecular biomarkers in human cancer | Peter Maslak, MD |
| Targeting CDH5 and simultaneously treating PSMA-positive and PSMA-negative prostate cancer with alpha particle therapy | Michael McDevitt, PhD |
| Camelid antibodies armed with alpha particles and directed at enzalutamide-treated prostate cancer | Michael McDevitt, PhD |
| A self-assembling synthetic clot to specifically infarct tumor tissue in vivo | Michael McDevitt, PhD |
| RNAi prophylaxis of chemotherapy-induced nephrotoxicity | Michael McDevitt, PhD |
| Optimizing EGFR Blockade in Human Glioblastoma | Ingo Mellinghoff, MD |
| Evaluation of epothilone analogs, synthetic microtubule stabilizing agents with potent anti-myeloma and anti-ovarian cancer action | Malcolm Moore, D.Phil. |
| Murine tumor xenograft models for preclinical drug development | Malcolm Moore, D.Phil. |
| Targeting activated ADAM17 for the treatment of epithelial ovarian cancer | Dimitar Nikolov, PhD |
| Function blocking antibodies against ADAM metalloproteases for inhibition of Eph, EGFR and Notch-dependent tumorigenesis | Dimitar Nikolov, PhD |
| Small-molecule inhibitors of Eph receptor signaling | Dimitar Nikolov, PhD |
| Single-chain anti-EphA2 antibodies for treatment of lymphoma and leukemia | Dimitar Nikolov, PhD |
| Real time polymerase chain reaction (PCR) for clinical and correlative studies | Stephen Nimer, MD |
| The role of arginine methyltransferases in the pathogenesis of myeloid malignancies | Stephen Nimer, MD |
| DNA vaccines against breast cancer: Synergy through targeting both tumor cells and tumor stroma | Francesca Orlandi, PhD |
| Chemical synthesis in carbohydrate-based cancer vaccines | Ouathek Ouerfelli, PhD |
| Overcoming acquired resistance to targeted therapy in lung cancer | William Pao, MD, PhD |
| Development of Gboxin, a benzimidazolium compound, as an antitumor reagent | Luis Parada, PhD |
| Protein chip biology system for high-thoughput screening | Gavril Pasternak MD, PhD |
| Sigma receptors: a novel anti-proliferative target for tumor therapy | Gavril Pasternak, MD, PhD |
| Structure activity of the sigma1 antagonist binding pocket | Gavril Pasternak, MD, PhD |
| Development of potent small molecule inhibitors of the cGAS-STING dsDNA-sensing immune pathway | Dinshaw Patel, PhD |
| Development of small molecule inhibitors of METTL3-METTL14 RNA methyltransferase complex as drugs against acute myeloid leukemia | Dinshaw Patel, PhD |
| T-cell precursors and allogeneic hematopoietic stem cell transplant | Miguel Perales, MD |
| SKI-N69: A candidate radiosensitizer | John Petrini, PhD |
| Modulation of DNA damage signaling pathways | John Petrini, PhD |
| Targeted synthetic immunity for activating site specific anti-tumor innate immune response | Nagavarakishore Pillarsetty, PhD |
| Site specific activation of γδ T cells for cancer immunotherapy applications | Nagavarakishore Pillarsetty, PhD |
| Targeted nuclear delivery of EGF-Auger emitting radioconjugates for cancer therapy | Nagavarakishore Pillarsetty, PhD |
| Genetically engineered CAR T cells for antigen-heterogeneous prostate cancer | Vladimir Ponomarev, MD, PhD |
| Tumor antigen-directed molecular imaging to strategize T-cell immunotherapy | Vladimir Ponomarev, MD, PhD |
| Evaluation of endothelial cell apoptosis in human cancer specimens in response to ionizing radiation | Elizabeth Poyner, MD, PhD |
| Novel structure derivatives of trehalose dimycolate as cancer vaccine adjuvants | Vivek Rao, PhD |
| Imaging of the Peripheral Nervous System | Thomas Reiner, PhD |
| Preclinical Testing of Hedgehog Inhibitors in Pancreatic Cancer | Marilyn Resh, PhD |
| Identification of hedgehog palmitoylation inhibitors | Marilyn Resh, PhD |
| Efficacy testing of TDI-3410, a Hedgehog Acyltransferase inhibitor, in mouse models of lung, breast and pancreatic cancer | Marilyn Resh, PhD |
| Targeting eIF4A in metastatic estrogen receptor positive breast cancer | Ezra Rosen, MD, PhD |
| Development and in vivo evaluation of clinical retroviral vectors designed to express high levels of mutant HSV thymidine kinase to increase the safety of T lymphocyte infusions | Isabelle Riviere, PhD |
| Development of improved TORC1 inhibitor-based therapies for the treatment of breast cancer and other carcinomas | Neal Rosen, MD, PhD; Daniel Heller |
| Development of improved TORC1 inhibitor-based therapies for the treatment of breast cancer and other carcinomas | Neal Rosen, MD, PhD; Daniel Heller |
| Development of combined inhibition of ERK and PI3K/AKT signaling as a strategy for the treatment of mutant RAS-dependent tumors | Neal Rosen, MD, PhD |
| DLL3 radioimmunoconjugates for high-grade neuroendocrine tumor imaging and therapy | Charles Rudin, MD, PhD |
| Design of combinatorial therapeutics | Chris Sander, PhD |
| Preclinical development of the anti-androgen A52 for prostate cancer therapy | Charles Sawyers, MD |
| Therapeutic self-assembling nanodevices | David Scheinberg, MD, PhD |
| Radiotherapy with targeted multivalent α-particle generators | David Scheinberg, MD, PhD |
| Development of novel inhibitors of SCCRO | Bhuvanesh Singh, MD |
| A novel class of peptidomimetic agents targeting tumor growth, angio-genesis, and metastases | Francis Sirotnak, PhD and David Scheinberg, MD, PhD |
| Modulation of chemotherapy sensitivity by alterations in PTEN/AKT signaling | David Solit, MD |
| Characterization of an RNA binding protein targeted by thalidomide analogues | David Spriggs, MD |
| MUC16 synthetic lethal screening in ovarian cancer | David Spriggs, MD |
| Development of novel menin inhibitors for glioma therapy | Viviane Tabar, MD |
| pdfSEAKER: Development of CAR T cells that express human peptide deformylase (hsPDF) to activate synergistic small-molecule prodrugs locally at tumors | Derek Tan, PhD |
| onSEAKER: Engineering CAR T cells to biosynthesize synergistic small molecule drugs in situ | Derek Tan, PhD |
| Targeted delivery of epigenetic small-molecule drugs by SEAKER cells | Derek Tan, PhD |
| A novel CAR T-cell platform for targeted, local biosynthesis of small-molecule therapeutics | Derek Tan, PhD |
| Studying Chk1-mediated signaling pathways using chemical genetics and functional imaging | Archie N. Tse, MD, PhD |
| Identification of novel small molecules with anti-proliferative action towards human lung cancer cell lines harboring oncogenic EGFR or KRAS | Harold Varmus, MD |
| ESSENCE compounds as tools for specific modulation of alternative splicing patterns | Sandra Vorlova, PhD |
| Development of NDR1/STK38 inhibitors in collaboration with the Tri-I TDI | Hans-Guido Wendel, MD |
| The oncogenic action of NRF2 depends on de-glycation by Fructosamine-3-kinase | Hans-Guido Wendel, MD |
| Defining the mechanism underlying GITR agonist activity | Jedd Wolchok, MD, PhD |
| Isolation TCRm modalities with broad reactivity to KRAS-HLA complex | Xinbo Yang, PhD |
| TMC-95A analogues as potential antitumor agents | Zhi-Qiang Yang, PhD |
| Controlled rate freezer for preclinical laboratory studies | James Young, MD |
| Janus kinase 2 (JAK2) as a therapeutic target in graft-versus-host disease | James Young, MD and Brian Betts, MD |
| Reversal of indoleamine 2,3-dioxygenase (IDO)-mediated suppression of tumor immunity stimulated by human dendritic cells | James Young, MD |